更新于：2024-11-21

Vitamin A/Vitamin E

维生素A/维生素E

更新于：2024-11-21

概要

概要

基本信息

药物类型

小分子化药

别名-

靶点

PXR x RARs

作用机制

PXR激动剂(孕烷X受体激动剂)、RARs激动剂(维甲酸受体家族激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

维生素a缺乏症维生素E缺乏症

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C29H50O2

InChIKeyGVJHHUAWPYXKBD-IEOSBIPESA-N

CAS号59-02-9

查看全部结构式(2)

关联

100 项与维生素A/维生素E 相关的临床结果

登录后查看更多信息

100 项与维生素A/维生素E 相关的转化医学

登录后查看更多信息

100 项与维生素A/维生素E 相关的专利（医药）

登录后查看更多信息

153

项与维生素A/维生素E 相关的文献（医药）

2024-06-01·International Journal for Vitamin and Nutrition Research

Analysis of the current vitamin A terminology and dietary regulations from vitamin A₁ to vitamin A₅

作者: Rühl, Ralph ; Bánáti, Diána

Abstract: Dietary recommendations on vitamin intake for human food fortification concerning vitamin A in various countries, larger economic zones and international organizations are mainly based on the Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO) “Codex Alimentarius standards”. The general vitamin A terminology is based on regulations of the International Union of Pure and Applied Chemistry (IUPAC) that are used to describe the involved derivatives. These regulations and terminology were set up in the middle of the last century. Starting with the decade of the 80ies in the 20th century a large improvement of molecular biological methodologies, background physiological mechanisms as well as analytical techniques contributed to a large diversification of this simply claimed vitamin A terminology. Unfortunately, the following terminology and governmental regulations for food fortification are imprecise and non-harmonized. In this article we tried to unravel this terminology for updating terminology, nutritional suggestions and governmental regulations for vitamin A, which are currently based on various uncertainties. According to the current regulations, the newly found vitamin A5/X can be included in the current vitamin A terminology as “vitamin A5” or alternatively or even in parallel as a new vitamin A-independent terminology as “vitamin X”. Based on the detailed knowledge of research from the early beginning of general vitamin A pathway identification towards detailed research of the last decades the commonly used and simplified term vitamin A with relevance for governmental recommendations on vitamin intake and food fortification advice was now more correctly sub-categorized to further vitamin A1, and A5 sub-categories with vitamin A1-alcohol as retinol, vitamin A2-alcohol as 3,4-didehydroretinol and vitamin A5-alcohol as 9- cis-13,14-dihydroretinol as their mainly relevant vitamin forms present in the human organism. Here we suggest and advise how the vitamin A terminology and further governmental regulations should be organized depending on a successful unraveling of the organization of the current vitamin A terminology.

2023-11-01·Journal of Cystic Fibrosis

The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis

Article

作者: Cogen, Jonathan D ; Nichols, David P ; Bartlett, Lauren E ; Hergenroeder, Georgene E ; Faino, Anna ; Ramos, Kathleen J ; Green, Nicole ; Bridges, Gracia ; McNamara, Sharon

BACKGROUNDWhile elexacaftor/tezacaftor/ivacaftor (ETI) has improved the pulmonary health of many people with cystic fibrosis (PwCF), less is known about ETI effectiveness for extra-pulmonary manifestations, including fat-soluble vitamin malabsorption. This study aims to evaluate ETI's impact on vitamin A, D, E, and international normalized ratio (INR, an indirect marker for Vitamin K) serum levels.METHODSRetrospective cohort study of PwCF ≥12 years receiving ETI. Vitamin levels up to four years preceding and up to two years following ETI initiation were collected. Pairwise comparisons of vitamin levels pre/post-ETI initiation were made using Wilcoxon signed rank and McNemar's tests. Linear mixed effect models were used to regress vitamin levels on time since starting ETI, ETI use (yes/no), the interaction between time and ETI use, and age.RESULTSTwo hundred and sixty-four participants met study inclusion, and 169 (64%) had post-ETI initiation vitamin levels. Median vitamin A levels increased from 422.0 to 471.0 mcg/L (p < 0.001), median vitamin D levels increased from 28.5 to 30.8 ng/mL (p = 0.003), and there were no significant changes in median vitamin E or INR. Vitamin A levels rose at a rate of 40.7 mcg/L/year (CI 11.3, 70.2) after ETI start.CONCLUSIONSETI initiation is associated with increased median vitamin A and vitamin D levels, but no change in median vitamin E or INR levels. Ongoing monitoring of vitamin levels after ETI initiation is needed to screen for potential deficiencies and toxicities, particularly in light of case reports of hypervitaminosis A following ETI initiation.

2023-08-08·JCI Insight

Natural history of retinitis pigmentosa based on genotype, vitamin A/E supplementation, and an electroretinogram biomarker

Article

作者: Bujakowska, Kinga M ; Pierce, Eric ; Weigel DiFranco, Carol ; Maher, Matthew ; Zampaglione, Erin ; Comander, Jason ; Sanderson, Kit ; Huckfeldt, Rachel M ; Zhao, Yan ; Place, Emily

BACKGROUNDA randomized clinical trial from 1984 to 1992 indicated that vitamin A supplementation had a beneficial effect on the progression of retinitis pigmentosa (RP), while vitamin E had an adverse effect.METHODSSequencing of banked DNA samples from that trial provided the opportunity to determine whether certain genotypes responded preferentially to vitamin supplementation.RESULTSThe genetic solution rate was 587 out of 765 (77%) of sequenced samples. Combining genetic solutions with electroretinogram outcomes showed that there were systematic differences in severity and progression seen among different genetic subtypes of RP, extending findings made for USH2A, RHO, RPGR, PRPF31, and EYS. Baseline electroretinogram 30-Hz flicker implicit time was an independent, strong predictor of progression rate. Using additional data and baseline implicit time as a predictor, the deleterious effect of vitamin E was still present. Surprisingly, the effect of vitamin A progression in the cohort as a whole was not detectable, with or without data from subsequent trials. Subgroup analyses are also discussed.CONCLUSIONOverall, genetic subtype and implicit time have significant predictive power for a patient's rate of progression, which is useful prognostically. While vitamin E supplementation should still be avoided, these data do not support a generalized neuroprotective effect of vitamin A for all types of RP.TRIAL REGISTRATIONClinicalTrials.gov NCT00000114, NCT00000116, and NCT00346333.FUNDINGFoundation Fighting Blindness and the National Eye Institute: R01 EY012910, R01 EY031036, R01 EY026904, and P30 EY014104.

100 项与维生素A/维生素E 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
维生素a缺乏症	中国	-	-
维生素E缺乏症	中国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Free Radic Biol Med	N/A	-	396	Vitamin C 1000 mg/day	觸獵鬱觸齋窪壓醖齋選(鬱製糧選齋築製積糧衊) = 鑰積艱鏇鑰積顧鏇鏇獵蓋鏇鹹淵築積積鑰夢艱 (願築遞艱餘積壓積醖蓋 ) 更多	-	2008-08-15
				Vitamin E 800 IU/day	觸獵鬱觸齋窪壓醖齋選(鬱製糧選齋築製積糧衊) = 壓糧鏇顧鏇夢廠觸醖醖蓋鏇鹹淵築積積鑰夢艱 (願築遞艱餘積壓積醖蓋 ) 更多